StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30250% above fair value
$149.52+3.19 (+2.18%)

Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%

Merck Fosamax by Quarter

Fosamax (alendronate, legacy pre-Organon spin-off) — Worldwide sales ($M) ($M)

QuarterlyAnnual

Merck Fosamax: $50M in Q4 2018, down 19.4% from a year earlier. No newer figure appears in the documents we track.

Latest, Q4 2018
50
Period ended Dec 31, 2018
Change on a year earlier
-19.4%
62 in Q4 2017
History
12 quarters
Since Q1 2016
Sources
2
Documents cited below

Where the Q4 2018 figure comes from

“|| Fosamax | 50 | 62 | -18 | 1 | (1 | ) | * | 49 | 62 | -21”

Source: Form 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗

Reported in Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedFosamax (alendronate, legacy pre-Organon spin-off) — Worldwide sales ($M) ($M)Year on yearSource
Q4 2018Dec 31, 201850-19.4%Form 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗
Q3 2018Sep 30, 201845-15.1%Form 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗
Q2 2018Jun 30, 201859-10.6%Form 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗
Q1 2018Mar 31, 201855-9.8%Form 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗
Q4 2017Dec 31, 201762-8.8%Form 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗
Q3 2017Sep 30, 201753-22.1%Form 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗
Q2 2017Jun 30, 201766-9.6%Form 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗
Q1 2017Mar 31, 201761-18.7%Form 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗
Q4 2016Dec 31, 201668–Form 8-K (a18-5152_1ex99d1.htm, filed 2018-02-02) ↗
Q3 2016Sep 30, 201668–Form 8-K (a18-5152_1ex99d1.htm, filed 2018-02-02) ↗
Q2 2016Jun 30, 201673–Form 8-K (a18-5152_1ex99d1.htm, filed 2018-02-02) ↗
Q1 2016Mar 31, 201675–Form 8-K (a18-5152_1ex99d1.htm, filed 2018-02-02) ↗

Breakdown

What makes up fosamax

Cite this data

StockData. (2026). Merck Fosamax ($M), quarterly Q1 2016–Q4 2018 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-fosamax

See every metric in the Merck KPI table. Data updated Oct 26, 2026.